Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06369285
Title A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
Acronym ALISCA-Breast1
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Puma Biotechnology, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.